Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:798-805
Published online before print January 22, 2008, doi: 10.1161/CIRCULATIONAHA.107.717595
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
117/6/798    most recent
CIRCULATIONAHA.107.717595v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Öhman, M. K.
Right arrow Articles by Eitzman, D. T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Öhman, M. K.
Right arrow Articles by Eitzman, D. T.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Obesity
Right arrow Animal models of human disease
Right arrow Risk Factors
Right arrow Genetically altered mice
Right arrowRelated Article

(Circulation. 2008;117:798-805.)
© 2008 American Heart Association, Inc.


Molecular Cardiology

Visceral Adipose Tissue Inflammation Accelerates Atherosclerosis in Apolipoprotein E–Deficient Mice

Miina K. Öhman, MD, PhD; Yuechun Shen, MD; Chinyere I. Obimba, BS; Andrew P. Wright, BS; Mark Warnock, BS; Daniel A. Lawrence, PhD; Daniel T. Eitzman, MD

From the University of Michigan, Department of Internal Medicine, Division of Cardiology, Ann Arbor (M.K.Ö., Y.S., C.I.O., A.P.W., M.W., D.A.L., D.T.E.), and Ann Arbor Veterans Adminstration Hospital, Ann Arbor (D.T.E.), Mich.

Correspondence to Daniel T. Eitzman, MD, University of Michigan, Cardiology, 7301A MSRB III, 1150 W Medical Center Dr, Ann Arbor, MI 48109–0644. E-mail deitzman{at}umich.edu

Received May 24, 2007; accepted December 5, 2007.

Background— Fat inflammation may play an important role in comorbidities associated with obesity such as atherosclerosis.

Methods and Results— To first establish feasibility of fat transplantation, epididymal fat pads were harvested from wild-type C57BL/6J mice and transplanted into leptin-deficient (Lepob/ob) mice. Fat transplantation produced physiological leptin levels and prevented obesity and infertility in Lepob/ob mice. However, the transplanted fat depots were associated with chronically increased macrophage infiltration with characteristics identical to those observed in fat harvested from obese animals. The inflammation in transplanted adipose depots was regulated by the same factors that have been implicated in endogenous fat inflammation such as monocyte chemoattractant protein-1. To determine whether this inflamed adipose depot could affect vascular disease in mice, epididymal fat depots were transplanted into atherosclerosis-prone apolipoprotein E–deficient ApoE–/– mice. Plasma from ApoE–/– mice receiving fat transplants contained increased leptin, resistin, and monocyte chemoattractant protein-1 compared with plasma from sham-operated ApoE–/– mice. Furthermore, mice transplanted with visceral fat developed significantly more atherosclerosis compared with sham-operated animals, whereas transplants with subcutaneous fat did not affect atherosclerosis despite a similar degree of fat inflammation. Treatment of transplanted ApoE–/– mice with pioglitazone decreased macrophage content of the transplanted visceral fat pad and reduced plasma monocyte chemoattractant protein-1. Importantly, pioglitazone also reduced atherosclerosis triggered by inflammatory visceral fat but had no protective effect on atherosclerosis in the absence of the visceral fat transplantation.

Conclusions— Our results indicate that visceral adipose-related inflammation accelerates atherosclerosis in mice. Drugs such as thiazolidinediones might be a useful strategy to specifically attenuate the vascular disease induced by visceral inflammatory fat.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 711-713. [Full Text]